Patients with chronic spontaneous urticaria experienced significant improvement with the use of Dupixent in a phase 3 trial conducted by Regeneron. The study showed that patients experienced an 8.64-point reduction in itch severity and a 15.86-point reduction in urticaria activity while using Dupixent compared to placebo. Additionally, 30% of patients on Dupixent achieved complete disease control. The positive results suggest that Dupixent has the potential to provide relief for those suffering from chronic spontaneous urticaria. Adverse events were reported in both study arms, with injection site reactions and accidental overdose being more common in the Dupixent arm.
Source link
Spontaneous chronic urticaria improvement seen with Dupixent treatment
